The Advanced Research Projects Agency for Health launched SPECTRA, a new research initiative aimed at transforming how autism spectrum disorder is diagnosed and treated through biomarkers, diagnostic tools, and precision medicine, on Sept. 17.
The program responds to a stated administration priority under HHS Secretary Robert F. Kennedy Jr. to address gaps in autism research and treatment, the department said.
With autism affecting an estimated one in 36 children in the United States, according to the Centers for Disease Control and Prevention, the initiative targets one of the most prevalent developmental conditions in the country. Diagnosis currently relies on behavioral observation and is often delayed until children are three or four years old — years after the earliest interventions could begin.
ARPA-H, modeled on the Defense Advanced Research Projects Agency, funds high-risk, high-reward research projects designed to produce breakthroughs that conventional research funding might not support. The agency was established in 2022 with bipartisan congressional support.
The SPECTRA program will fund projects at universities, hospitals, and private research firms focused on identifying biological markers for autism that could enable earlier and more consistent diagnosis, the department said. The initiative will also support development of individualized treatment plans based on a patient’s specific biological profile.
For the families of children with autism, the promise of earlier diagnosis through objective biomarkers — rather than subjective behavioral assessments — could mean earlier access to therapies that have been shown to improve outcomes when started in infancy.
Kennedy has made autism research a personal priority, citing concerns about rising diagnosis rates and calling for expanded investigation into environmental and biological causes.
The Autism Society of America and Autism Speaks have both advocated for increased federal investment in diagnostic innovation and precision treatment approaches.
ARPA-H did not immediately disclose the total funding allocation for SPECTRA or the timeline for initial project awards.